Contact
searchSearch
HMP Global

Non-Small Cell Lung Cancer Topic Center

Featured Article

News
Amivantamab–Lazertinib Extends Progression-Free Survival in Untreated EGFR-Mutated NSCLC
10/11/2024
Progression-free survival was significantly longer with amivantamab–lazertinib compared with osimertinib as first-line treatment of untreated EGFR (epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC),...
Progression-free survival was significantly longer with amivantamab–lazertinib compared with osimertinib as first-line treatment of untreated EGFR (epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC),...
Progression-free survival was...
10/11/2024
First Report Managed Care
News
Family History of Cancer Impacts Survival and Treatment Outcomes in Patients With NSCLC
10/11/2024
A recent study highlights the significant impact of family tumor history on disease-free survival in patients with non-small cell lung cancer (NSCLC), suggesting that familial cancer backgrounds could be critical in tailoring treatment...
A recent study highlights the significant impact of family tumor history on disease-free survival in patients with non-small cell lung cancer (NSCLC), suggesting that familial cancer backgrounds could be critical in tailoring treatment...
A recent study highlights the...
10/11/2024
First Report Managed Care
Alexander Spira, MD, PhD
Videos
Unmet Needs in the Treatment and Management of Non–Small Cell Lung Cancer
09/26/2024
Alexander I. Spira, MD, PhD, discusses significant unmet needs in the treatment and management of non–small cell lung cancer (NSCLC).
Alexander I. Spira, MD, PhD, discusses significant unmet needs in the treatment and management of non–small cell lung cancer (NSCLC).
Alexander I. Spira, MD, PhD,...
09/26/2024
First Report Managed Care
News
Challenges and Emerging Strategies in Overcoming Resistance in EGFR-Mutant NSCLC
09/10/2024
Despite promising early results, adding immunotherapy to standard chemotherapy does not significantly improve outcomes for patients with EGFR-mutant non-small cell lung cancer (NSCLC) who have progressed after initial targeted therapy,...
Despite promising early results, adding immunotherapy to standard chemotherapy does not significantly improve outcomes for patients with EGFR-mutant non-small cell lung cancer (NSCLC) who have progressed after initial targeted therapy,...
Despite promising early results,...
09/10/2024
First Report Managed Care
News
Real-World Data Reveal Effectiveness of Systemic Therapies for BRAF Mutation-Positive NSCLC
03/17/2023
"Future studies to clarify the role of co-mutations on response to both dual-targeted BRAF/MEK inhibition and ICI-based regimens may be important to treatment selection and optimization of patient outcome," authors advised.
"Future studies to clarify the role of co-mutations on response to both dual-targeted BRAF/MEK inhibition and ICI-based regimens may be important to treatment selection and optimization of patient outcome," authors advised.
"Future studies to clarify the...
03/17/2023
First Report Managed Care
News
PD-1 Inhibitors Improve Survival in Patients With Advanced EGFR-Mutant NSCLC After TKI Resistance
03/10/2023
A real-world study tested the efficacy and safety of PD-1 inhibitors for patients with non-small cell lung cancer after treatment with tyrosine kinase inhibitors failed.
A real-world study tested the efficacy and safety of PD-1 inhibitors for patients with non-small cell lung cancer after treatment with tyrosine kinase inhibitors failed.
A real-world study tested the...
03/10/2023
First Report Managed Care
News
Combination Therapy Significantly Improves PFS in Patients With NSCLC With High Tumor Mutational Burden
02/15/2023
Chemoradiation and adjuvant monoclonal antibody therapy significantly improved outcomes in patients with locally advanced non-small cell lung cancer with high tumor mutational burden.
Chemoradiation and adjuvant monoclonal antibody therapy significantly improved outcomes in patients with locally advanced non-small cell lung cancer with high tumor mutational burden.
Chemoradiation and adjuvant...
02/15/2023
First Report Managed Care
News
Robotic Lobectomy Feasible for Older Adults With NSCLC, Analysis Finds
01/27/2023
Researchers studied the postoperative outcomes of patients over 75 years of age who underwent a robotic-assisted lobectomy to treat non-small cell lung cancer.
Researchers studied the postoperative outcomes of patients over 75 years of age who underwent a robotic-assisted lobectomy to treat non-small cell lung cancer.
Researchers studied the...
01/27/2023
First Report Managed Care
Headshot of Nasser Altorki, MD, on a blue background underneath the PopHealth Perspectives logo.
Podcasts
Treatment Shows Disease-free Survival Benefit in Patients With NSCLC
11/09/2021
Nasser Altorki, MD, chief of thoracic surgery, New York Presbyterian-Weill Cornell Medicine, discusses the findings from the IMpower010 study, in which adjuvant atezolizumab resulted in a disease-free survival benefit that was superior to...
Nasser Altorki, MD, chief of thoracic surgery, New York Presbyterian-Weill Cornell Medicine, discusses the findings from the IMpower010 study, in which adjuvant atezolizumab resulted in a disease-free survival benefit that was superior to...
Nasser Altorki, MD, chief of...
11/09/2021
First Report Managed Care
Headshot of Alex Spira, Virginia Cancer Specialists Research Institute, on a blue background underneath the PopHealth Perspectives logo.
Podcasts
Treatment Options and Unmet Need in Non-small Cell Lung Cancer
10/08/2021
Alex Spira, MD, PhD, FACP, director of the Virginia Cancer Specialists Research Institute, medical director at US Oncology Network, provides an overview of currently available treatment options in non-small cell lung cancer, and describes the...
Alex Spira, MD, PhD, FACP, director of the Virginia Cancer Specialists Research Institute, medical director at US Oncology Network, provides an overview of currently available treatment options in non-small cell lung cancer, and describes the...
Alex Spira, MD, PhD, FACP,...
10/08/2021
First Report Managed Care
Improving Survival Rates Among Patients With NSCLC Using New, Effective Treatment Strategy
Videos
Improving Survival Rates Among Patients With NSCLC Using New, Effective Treatment Strategy
06/18/2020
Roy S Herbst, MD, PhD, ensign professor of medicine and professor of pharmacology, chief of medical oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses the results of the ADAURA study that examined the use of Tagrisso...
Roy S Herbst, MD, PhD, ensign professor of medicine and professor of pharmacology, chief of medical oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses the results of the ADAURA study that examined the use of Tagrisso...
Roy S Herbst, MD, PhD, ensign...
06/18/2020
First Report Managed Care

Newsfeed

News
Amivantamab–Lazertinib Extends Progression-Free Survival in Untreated EGFR-Mutated NSCLC
10/11/2024
Progression-free survival was significantly longer with amivantamab–lazertinib compared with osimertinib as first-line treatment of untreated EGFR (epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC),...
Progression-free survival was significantly longer with amivantamab–lazertinib compared with osimertinib as first-line treatment of untreated EGFR (epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC),...
Progression-free survival was...
10/11/2024
First Report Managed Care
News
Family History of Cancer Impacts Survival and Treatment Outcomes in Patients With NSCLC
10/11/2024
A recent study highlights the significant impact of family tumor history on disease-free survival in patients with non-small cell lung cancer (NSCLC), suggesting that familial cancer backgrounds could be critical in tailoring treatment...
A recent study highlights the significant impact of family tumor history on disease-free survival in patients with non-small cell lung cancer (NSCLC), suggesting that familial cancer backgrounds could be critical in tailoring treatment...
A recent study highlights the...
10/11/2024
First Report Managed Care
News
Challenges and Emerging Strategies in Overcoming Resistance in EGFR-Mutant NSCLC
09/10/2024
Despite promising early results, adding immunotherapy to standard chemotherapy does not significantly improve outcomes for patients with EGFR-mutant non-small cell lung cancer (NSCLC) who have progressed after initial targeted therapy,...
Despite promising early results, adding immunotherapy to standard chemotherapy does not significantly improve outcomes for patients with EGFR-mutant non-small cell lung cancer (NSCLC) who have progressed after initial targeted therapy,...
Despite promising early results,...
09/10/2024
First Report Managed Care
News
Real-World Data Reveal Effectiveness of Systemic Therapies for BRAF Mutation-Positive NSCLC
03/17/2023
"Future studies to clarify the role of co-mutations on response to both dual-targeted BRAF/MEK inhibition and ICI-based regimens may be important to treatment selection and optimization of patient outcome," authors advised.
"Future studies to clarify the role of co-mutations on response to both dual-targeted BRAF/MEK inhibition and ICI-based regimens may be important to treatment selection and optimization of patient outcome," authors advised.
"Future studies to clarify the...
03/17/2023
First Report Managed Care
News
PD-1 Inhibitors Improve Survival in Patients With Advanced EGFR-Mutant NSCLC After TKI Resistance
03/10/2023
A real-world study tested the efficacy and safety of PD-1 inhibitors for patients with non-small cell lung cancer after treatment with tyrosine kinase inhibitors failed.
A real-world study tested the efficacy and safety of PD-1 inhibitors for patients with non-small cell lung cancer after treatment with tyrosine kinase inhibitors failed.
A real-world study tested the...
03/10/2023
First Report Managed Care
News
Combination Therapy Significantly Improves PFS in Patients With NSCLC With High Tumor Mutational Burden
02/15/2023
Chemoradiation and adjuvant monoclonal antibody therapy significantly improved outcomes in patients with locally advanced non-small cell lung cancer with high tumor mutational burden.
Chemoradiation and adjuvant monoclonal antibody therapy significantly improved outcomes in patients with locally advanced non-small cell lung cancer with high tumor mutational burden.
Chemoradiation and adjuvant...
02/15/2023
First Report Managed Care
News
Robotic Lobectomy Feasible for Older Adults With NSCLC, Analysis Finds
01/27/2023
Researchers studied the postoperative outcomes of patients over 75 years of age who underwent a robotic-assisted lobectomy to treat non-small cell lung cancer.
Researchers studied the postoperative outcomes of patients over 75 years of age who underwent a robotic-assisted lobectomy to treat non-small cell lung cancer.
Researchers studied the...
01/27/2023
First Report Managed Care
News
Checkpoint Inhibitors To Play Major Role in Treatment of NSCLC
12/15/2017
A recent study in The Ochsner Journal examined the role of checkpoint inhibition in non–small cell lung cancer treatment. 
A recent study in The Ochsner Journal examined the role of checkpoint inhibition in non–small cell lung cancer treatment. 
A recent study in The Ochsner...
12/15/2017
First Report Managed Care
News
Recent Research Reports New Treatment Options for NSCLC
11/21/2017
Recent research, reported in The New England Journal of Medicine, showed that Tagrisso improved outcomes among non-small cell lung cancer (NSCLC) patients with an epidermal growth factor receptor.
Recent research, reported in The New England Journal of Medicine, showed that Tagrisso improved outcomes among non-small cell lung cancer (NSCLC) patients with an epidermal growth factor receptor.
Recent research, reported in The...
11/21/2017
First Report Managed Care
News
Additional NSCLC Treatments Needed to Reduce Post-Progression Costs
11/16/2017
A recent poster at AMCP Nexus 2017 found that costs during TKI treatment for Non-small cell lung cancer were similar to costs after progression, due to high hospital utilization.
A recent poster at AMCP Nexus 2017 found that costs during TKI treatment for Non-small cell lung cancer were similar to costs after progression, due to high hospital utilization.
A recent poster at AMCP Nexus...
11/16/2017
First Report Managed Care
News
Using Deep Learning to Measure MS-Specific Brain Damage Beyond Aging
11/11/2024
A new study published in Neurology aimed to differentiate age-related brain changes from multiple sclerosis (MS)-specific neurodegeneration using MRI.
A new study published in Neurology aimed to differentiate age-related brain changes from multiple sclerosis (MS)-specific neurodegeneration using MRI.
A new study published in...
11/11/2024
First Report Managed Care
News
Adverse Event Data Suggest Selective β1-blockers Pose Asthma Risk
11/11/2024
The risks of asthma and asthma-like adverse events appear to be higher with selective β1-blockers than with nonselective blockers and α- and β-blockers.
The risks of asthma and asthma-like adverse events appear to be higher with selective β1-blockers than with nonselective blockers and α- and β-blockers.
The risks of asthma and...
11/11/2024
First Report Managed Care
News
RNAi Therapies Offer New Hope for Patients With Hereditary Transthyretin Amyloidosis
11/08/2024
RNA interference (RNAi)-based treatments for hereditary transthyretin amyloidosis (ATTR) have shown remarkable promise, offering new hope for patients with this rare but devastating genetic disorder.
RNA interference (RNAi)-based treatments for hereditary transthyretin amyloidosis (ATTR) have shown remarkable promise, offering new hope for patients with this rare but devastating genetic disorder.
RNA interference (RNAi)-based...
11/08/2024
First Report Managed Care
News
Revolutionary Single-Dose Gene Therapy Offers New Hope for Adults with Hemophilia B
11/08/2024
A groundbreaking gene therapy for hemophilia B has shown remarkable success in reducing bleeding episodes and improving the quality of life for adult patients, according to a recent international phase III clinical trial.
A groundbreaking gene therapy for hemophilia B has shown remarkable success in reducing bleeding episodes and improving the quality of life for adult patients, according to a recent international phase III clinical trial.
A groundbreaking gene therapy...
11/08/2024
First Report Managed Care
News
Real-World Evidence Supports Efficacy and Safety of Selexipag in Patients With Pulmonary Arterial Hypertension
11/07/2024
Real-world data shows selexipag effectively improves functional class and risk category outcomes in patients with pulmonary arterial hypertension, regardless of maintenance dose.
Real-world data shows selexipag effectively improves functional class and risk category outcomes in patients with pulmonary arterial hypertension, regardless of maintenance dose.
Real-world data shows selexipag...
11/07/2024
First Report Managed Care
News
Clinical Predictors of One-Year Seizure Freedom After SLAH
11/06/2024
A study published in Annals of Clinical and Translational Neurology aimed to predict 1-year seizure freedom for patients undergoing stereotactic laser amygdalohippocampotomy (SLAH) for mesial temporal lobe epilepsy (MTLE) using a set of...
A study published in Annals of Clinical and Translational Neurology aimed to predict 1-year seizure freedom for patients undergoing stereotactic laser amygdalohippocampotomy (SLAH) for mesial temporal lobe epilepsy (MTLE) using a set of...
A study published in Annals of...
11/06/2024
First Report Managed Care
News
Efficacy and Outcomes of Neoadjuvant Immunotherapy in Lung Cancer
11/05/2024
A meta-analysis of 43 studies suggests that neoadjuvant chemoimmunotherapy may benefit patients with resectable NSCLC and low tumor PD-L1 levels for event-free survival, showing superior outcomes compared to neoadjuvant chemotherapy.
A meta-analysis of 43 studies suggests that neoadjuvant chemoimmunotherapy may benefit patients with resectable NSCLC and low tumor PD-L1 levels for event-free survival, showing superior outcomes compared to neoadjuvant chemotherapy.
A meta-analysis of 43 studies...
11/05/2024
First Report Managed Care
News
FDA Grants Accelerated Approval for Asciminib as First-Line Treatment in Ph+CML-CP
11/01/2024
Novartis received accelerated approval by the US Food and Drug Administration (FDA) for asciminib, a medication for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+CML-CP).
Novartis received accelerated approval by the US Food and Drug Administration (FDA) for asciminib, a medication for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+CML-CP).
Novartis received accelerated...
11/01/2024
First Report Managed Care
News
HHS Faces Legal Action From 10 Hospitals Over 2023 Medicare Advantage Rule and Reimbursement Calculations
10/30/2024
Ten hospitals sued the US Department of Health and Human Services (HHS), claiming that they were underpaid Medicare reimbursements for serving low-income patients.
Ten hospitals sued the US Department of Health and Human Services (HHS), claiming that they were underpaid Medicare reimbursements for serving low-income patients.
Ten hospitals sued the US...
10/30/2024
First Report Managed Care
News
Impact of Immune Checkpoint Inhibitors on Multiple Sclerosis Treatment Outcomes
10/29/2024
Relapses and progression of multiple sclerosis were rare in patients treated with immune checkpoint inhibitors, according to a study presented at the American Academy of Neurology 2024 Annual Meeting.
Relapses and progression of multiple sclerosis were rare in patients treated with immune checkpoint inhibitors, according to a study presented at the American Academy of Neurology 2024 Annual Meeting.
Relapses and progression of...
10/29/2024
First Report Managed Care

Insights

Alexander Spira, MD, PhD
Videos
Unmet Needs in the Treatment and Management of Non–Small Cell Lung Cancer
09/26/2024
Alexander I. Spira, MD, PhD, discusses significant unmet needs in the treatment and management of non–small cell lung cancer (NSCLC).
Alexander I. Spira, MD, PhD, discusses significant unmet needs in the treatment and management of non–small cell lung cancer (NSCLC).
Alexander I. Spira, MD, PhD,...
09/26/2024
First Report Managed Care
Headshot of Nasser Altorki, MD, on a blue background underneath the PopHealth Perspectives logo.
Podcasts
Treatment Shows Disease-free Survival Benefit in Patients With NSCLC
11/09/2021
Nasser Altorki, MD, chief of thoracic surgery, New York Presbyterian-Weill Cornell Medicine, discusses the findings from the IMpower010 study, in which adjuvant atezolizumab resulted in a disease-free survival benefit that was superior to...
Nasser Altorki, MD, chief of thoracic surgery, New York Presbyterian-Weill Cornell Medicine, discusses the findings from the IMpower010 study, in which adjuvant atezolizumab resulted in a disease-free survival benefit that was superior to...
Nasser Altorki, MD, chief of...
11/09/2021
First Report Managed Care
Headshot of Alex Spira, Virginia Cancer Specialists Research Institute, on a blue background underneath the PopHealth Perspectives logo.
Podcasts
Treatment Options and Unmet Need in Non-small Cell Lung Cancer
10/08/2021
Alex Spira, MD, PhD, FACP, director of the Virginia Cancer Specialists Research Institute, medical director at US Oncology Network, provides an overview of currently available treatment options in non-small cell lung cancer, and describes the...
Alex Spira, MD, PhD, FACP, director of the Virginia Cancer Specialists Research Institute, medical director at US Oncology Network, provides an overview of currently available treatment options in non-small cell lung cancer, and describes the...
Alex Spira, MD, PhD, FACP,...
10/08/2021
First Report Managed Care
Improving Survival Rates Among Patients With NSCLC Using New, Effective Treatment Strategy
Videos
Improving Survival Rates Among Patients With NSCLC Using New, Effective Treatment Strategy
06/18/2020
Roy S Herbst, MD, PhD, ensign professor of medicine and professor of pharmacology, chief of medical oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses the results of the ADAURA study that examined the use of Tagrisso...
Roy S Herbst, MD, PhD, ensign professor of medicine and professor of pharmacology, chief of medical oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses the results of the ADAURA study that examined the use of Tagrisso...
Roy S Herbst, MD, PhD, ensign...
06/18/2020
First Report Managed Care
Videos
Bridging the Gaps in Prior Authorization: Challenges, Solutions, and Collaboration for Better Patient Care
11/13/2024
David Sand, MD, MBA, chief medical officer at ZeOmega, discusses the challenges of prior authorization, emphasizing the need for transparency, evidence-based standards, collaboration between payers and providers, and the potential for...
David Sand, MD, MBA, chief medical officer at ZeOmega, discusses the challenges of prior authorization, emphasizing the need for transparency, evidence-based standards, collaboration between payers and providers, and the potential for...
David Sand, MD, MBA, chief...
11/13/2024
First Report Managed Care
Richard Lipton, MD
Videos
The Evolving Role of CGRP-targeting Therapies in Migraine Prevention
10/31/2024
Richard Lipton, MD, provides insights on the American Headache Society’s position statement update on calcitonin gene-related peptide (CGRP)-targeting therapies as a first-line option for the prevention of migraine.
Richard Lipton, MD, provides insights on the American Headache Society’s position statement update on calcitonin gene-related peptide (CGRP)-targeting therapies as a first-line option for the prevention of migraine.
Richard Lipton, MD, provides...
10/31/2024
First Report Managed Care
Alexander Spira, MD, PhD
Videos
Unmet Needs in the Treatment and Management of Non–Small Cell Lung Cancer
09/26/2024
Alexander I. Spira, MD, PhD, discusses significant unmet needs in the treatment and management of non–small cell lung cancer (NSCLC).
Alexander I. Spira, MD, PhD, discusses significant unmet needs in the treatment and management of non–small cell lung cancer (NSCLC).
Alexander I. Spira, MD, PhD,...
09/26/2024
First Report Managed Care
Videos
Treatment Options for NSCLC: A Discussion on Coverage, Clinical Outcomes, and Payer Perspectives
09/25/2024
Learn about research developments in 1L therapy for NSCLC patients with EGFR mutations and how outcomes may impact coverage and reimbursement decisions for insurers.
Learn about research developments in 1L therapy for NSCLC patients with EGFR mutations and how outcomes may impact coverage and reimbursement decisions for insurers.
Learn about research...
09/25/2024
First Report Managed Care
Title Card
Videos
Addressing the Root Cause of a Common Ocular Condition: A Virtual Roundtable
09/04/2024
View a roundtable discussion on Demodex blepharitis, a prevalent ocular condition that often goes undiagnosed in patients.
View a roundtable discussion on Demodex blepharitis, a prevalent ocular condition that often goes undiagnosed in patients.
View a roundtable discussion on...
09/04/2024
First Report Managed Care
Sid Devarakonda
Podcasts
Frontline Treatment Landscape Advancements for Non-Small Cell Lung Cancer
08/28/2024
Tune in as we speak with a guest oncology expert about the progress in treating non-small cell lung cancer, targeted therapies and immunotherapy, and the challenges of early detection and screening options covered by health plans.
Tune in as we speak with a guest oncology expert about the progress in treating non-small cell lung cancer, targeted therapies and immunotherapy, and the challenges of early detection and screening options covered by health plans.
Tune in as we speak with a guest...
08/28/2024
First Report Managed Care
Jordan Bazinsky
Videos
Addressing Health Disparities and Promoting Equity: The Role of Advanced Imaging Solutions
08/15/2024
Guest expert Jordan Bazinsky discusses the challenges facing the medical imaging industry, the potential of AI and emerging technologies, the role of advanced imaging solutions in promoting health equity, and the key trends and challenges...
Guest expert Jordan Bazinsky discusses the challenges facing the medical imaging industry, the potential of AI and emerging technologies, the role of advanced imaging solutions in promoting health equity, and the key trends and challenges...
Guest expert Jordan Bazinsky...
08/15/2024
First Report Managed Care
Farrukh Awan, MD
Videos
Promising Therapies and Clinical Trials for Chronic Lymphocytic Leukemia
08/14/2024
Farrukh Awan, MD, highlights promising therapies and clinical trials within the field of chronic lymphocytic leukemia (CLL).
Farrukh Awan, MD, highlights promising therapies and clinical trials within the field of chronic lymphocytic leukemia (CLL).
Farrukh Awan, MD, highlights...
08/14/2024
Journal of Clinical Pathways
Hayward
Videos
Evolving Health Care Contact Centers Into Drivers of Value-Based Care
07/31/2024
Discover how health care contact centers can transform into drivers of value-based care through AI, automation, upskilling agents, and rethinking workflows and metrics to improve patient outcomes and population health.
Discover how health care contact centers can transform into drivers of value-based care through AI, automation, upskilling agents, and rethinking workflows and metrics to improve patient outcomes and population health.
Discover how health care contact...
07/31/2024
First Report Managed Care
Lucille Accetta Headshot
Videos
Enhancing Patient Medication Adherence: Insights and Strategies From Asembia 2024
06/11/2024
Lucille Accetta, PharmD, MBA, MSPH, Senior Vice President of CVS Specialty Operations
Key stakeholders in the health care industry gathered to discuss prevalent topics at this year's Asembia annual summit. Medication adherence emerged as one of the most talked-about issues. In a session led by Lucille Accetta, PharmD, MBA,...
Key stakeholders in the health care industry gathered to discuss prevalent topics at this year's Asembia annual summit. Medication adherence emerged as one of the most talked-about issues. In a session led by Lucille Accetta, PharmD, MBA,...
Key stakeholders in the health...
06/11/2024
First Report Managed Care

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use